韓國Deargen公司、美國佐治亞州亞特蘭大市埃默里大學、韓國天安市擔國大學自然科學學院聯,利用藥物-靶點相互作用模型(MT-DTI),預測了與新型冠狀病毒(2019-nCoV) 3C樣蛋白酶、RNA依賴RNA聚合酶、解旋酶、3 '- 5 '核酸外切酶、內切RNA酶、內切RNA酶的藥物及化合物。
抑制新型冠狀病毒(2019-nCoV) 3C樣蛋白酶的DTI預測結果
項目號 | 產品名稱 | 純度 | CAS | 規格 |
---|---|---|---|---|
A125825 | Atazanavir 阿扎那韋 |
- | 198904-31-3 | 10mg,50mg,250mg,5g |
E135556 | Efavirenz 依法韋侖 |
≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |
R126586 | 利托那韋 Ritonavir |
≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |
D127636 | 多替拉韋 Dolutegravir |
≥99% | 1051375-16-6 | 5mg,10mg,50mg |
A126103 | Asunaprevir 阿那匹韋 |
≥98% | 630420-16-5 | 5mg,10mg,50mg,250mg |
S127117 | Simeprevir 西咪匹韋 |
≥99% | 923604-59-5 | 5mg,10mg,50mg,100mg |
抑制新型冠狀病毒(2019-nCoV)的RNA依賴RNA聚合酶的DTI預測結果
項目號 | 產品名稱 | 純度 | CAS | 規格 |
---|---|---|---|---|
M124903 | MK-5172 | 98% | 1350514-68-9 | 5mg,10mg |
G129109 | Ganciclovir 更昔洛韋 |
≥98.0% | 82410-32-0 | 1g,5g,25g,100g |
A125825 | Atazanavir 阿扎那韋 |
- | 198904-31-3 | 10mg,50mg,250mg,5g |
D127186 | Daclatasvir(BMS-790052) | ≥98% | 1009119-64-5 | 10mg,50mg,250mg |
E126710 | Etravirine (TMC125) | ≥95% | 269055-15-4 | 5mg,25mg,100mg,1g |
E181466 | Entecavir 恩替卡韋 |
98% | 142217-69-4 | 250mg,1g |
E135556 | Efavirenz 依法韋侖 |
≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |
A126103 | Asunaprevir 阿那匹韋 |
≥98% | 630420-16-5 | 5mg,10mg,50mg,250mg |
A126552 | Abacavir 阿巴卡韋 |
≥98.0% | 136470-78-5 | 1g,5g |
D127636 | 多替拉韋 Dolutegravir |
≥99% | 1051375-16-6 | 5mg,10mg,50mg |
V127611 | VX-222 (VCH-222, Lomibuvir) | ≥99% | 1026785-59-0 | 5mg,10mg,50mg |
P125160 | Penciclovir 噴昔洛韋 |
≥99% | 39809-25-1 | 50mg,250mg,1g |
D127014 | Danoprevir (ITMN-191) | ≥95% | 850876-88-9 | 2mg,5mg,25mg |
R126586 | 利托那韋 Ritonavir |
≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |
S126514 | 沙奎那韋 Saquinavir |
≥98% | 127779-20-8 | 25mg,100mg |
R129802 | Raltegravir(MK-0518) | ≥97% | 518048-05-0 | 5mg,10mg,50mg,1g |
抑制新型冠狀病毒(2019-nCoV)的解旋酶的DTI預測結果
項目號 | 中文名稱 | 規格 | CAS | 包裝 |
---|---|---|---|---|
S127117 | Simeprevir 西咪匹韋 |
≥99% | 923604-59-5 | 5mg,10mg,50mg,100mg |
A125825 | Atazanavir 阿扎那韋 |
- | 198904-31-3 | 10mg,50mg,250mg,5g |
M124903 | MK-5172 | 98% | 1350514-68-9 | 5mg,10mg |
A126103 | Asunaprevir 阿那匹韋 |
≥98% | 630420-16-5 | 5mg,10mg,50mg,250mg |
T126775 | Telaprevir 特拉匹韋 |
≥98% | 402957-28-2 | 5mg,10mg,50mg |
R126586 | 利托那韋 Ritonavir |
≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |
L299096 | 洛比那韋 Lopinavir |
95% | 192725-17-0 | 10mg,50mg,250mg,1g |
L129320 | 洛比那韋 Lopinavir |
≥99% | 192725-17-0 | 10mg,50mg,100mg,250mg,1g |
D125841 | 達蘆那韋 Darunavir |
98% | 206361-99-1 | 5mg,10mg,50mg,250mg,1g |
G129109 | Ganciclovir 更昔洛韋 |
≥98.0% | 82410-32-0 | 1g,5g,25g,100g |
P125160 | Penciclovir 噴昔洛韋 |
≥99% | 39809-25-1 | 50mg,250mg,1g |
E126710 | Etravirine (TMC125) | ≥95% | 269055-15-4 | 5mg,25mg,100mg,1g |
R129802 | Raltegravir(MK-0518) | ≥97% | 518048-05-0 | 5mg,10mg,50mg,1g |
D127636 | 多替拉韋 Dolutegravir |
≥99% | 1051375-16-6 | 5mg,10mg,50mg |
N137745 | 奈非那韋 Nelfinavir Mesylate |
98% | 159989-65-8 | 10mg,50mg,250mg |
E135556 | Efavirenz 依法韋侖 |
≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |
E181466 | Entecavir 恩替卡韋 |
98% | 142217-69-4 | 250mg,1g |
R126586 | 利托那韋 Ritonavir |
≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |
V127611 | VX-222 (VCH-222, Lomibuvir) | ≥99% | 1026785-59-0 | 5mg,10mg,50mg |
抑制新型冠狀病毒(2019-nCoV)的3 '- 5 '核酸外切酶的DTI預測結果
項目號 | 中文名稱 | 規格 | CAS | 包裝 |
---|---|---|---|---|
S127117 | Simeprevir 西咪匹韋 |
≥99% | 923604-59-5 | 5mg,10mg,50mg,100mg |
E135556 | Efavirenz 依法韋侖 |
≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |
D127014 | Danoprevir (ITMN-191) | ≥95% | 850876-88-9 | 2mg,5mg,25mg |
G129109 | Ganciclovir 更昔洛韋 |
≥98.0% | 82410-32-0 | 1g,5g,25g,100g |
P125160 | Penciclovir 噴昔洛韋 |
≥99% | 39809-25-1 | 50mg,250mg,1g |
A125825 | Atazanavir 阿扎那韋 |
- | 198904-31-3 | 10mg,50mg,250mg,5g |
E181466 | Entecavir 恩替卡韋 |
98% | 142217-69-4 | 250mg,1g |
D127186 | Daclatasvir(BMS-790052) | ≥98% | 1009119-64-5 | 10mg,50mg,250mg |
M124903 | MK-5172 | 98% | 1350514-68-9 | 5mg,10mg |
A126103 | Asunaprevir 阿那匹韋 |
≥98% | 630420-16-5 | 5mg,10mg,50mg,250mg |
R126586 | 利托那韋 Ritonavir |
≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |
V127611 | VX-222 (VCH-222, Lomibuvir) | ≥99% | 1026785-59-0 | 5mg,10mg,50mg |
D125841 | 達蘆那韋 Darunavir |
98% | 206361-99-1 | 5mg,10mg,50mg,250mg,1g |
R129802 | Raltegravir(MK-0518) | ≥97% | 518048-05-0 | 5mg,10mg,50mg,1g |
D127636 | 多替拉韋 Dolutegravir |
≥99% | 1051375-16-6 | 5mg,10mg,50mg |
L299096 | 洛比那韋 Lopinavir |
95% | 192725-17-0 | 10mg,50mg,250mg,1g |
L129320 | 洛比那韋 Lopinavir |
≥99% | 192725-17-0 | 10mg,50mg,100mg,250mg,1g |
抑制新型冠狀病毒(2019-nCoV)的內切RNA酶的DTI預測結果
項目號 | 中文名稱 | 規格 | CAS | 包裝 |
---|---|---|---|---|
E135556 | Efavirenz 依法韋侖 |
≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |
A125825 | Atazanavir 阿扎那韋 |
- | 198904-31-3 | 10mg,50mg,250mg,5g |
R126586 | 利托那韋 Ritonavir |
≥98% | 155213-67-5 | 10mg,50mg,250mg,500mg |
D127014 | Danoprevir (ITMN-191) | ≥95% | 850876-88-9 | 2mg,5mg,25mg |
M124903 | MK-5172 | 98% | 1350514-68-9 | 5mg,10mg |
D127636 | 多替拉韋 Dolutegravir |
≥99% | 1051375-16-6 | 5mg,10mg,50mg |
V127611 | VX-222 (VCH-222, Lomibuvir) | ≥99% | 1026785-59-0 | 5mg,10mg,50mg |
L299096 | 洛比那韋 Lopinavir |
95% | 192725-17-0 | 10mg,50mg,250mg,1g |
L129320 | 洛比那韋 Lopinavir |
≥99% | 192725-17-0 | 10mg,50mg,100mg,250mg,1g |
D125841 | 達蘆那韋 Darunavir |
98% | 206361-99-1 | 5mg,10mg,50mg,250mg,1g |
N137745 | 奈非那韋 Nelfinavir Mesylate |
98% | 159989-65-8 | 10mg,50mg,250mg |
T126775 | Telaprevir 特拉匹韋 |
≥98% | 402957-28-2 | 5mg,10mg,50mg |
A126552 | Abacavir 阿巴卡韋 |
≥98.0% | 136470-78-5 | 1g,5g |
R129802 | Raltegravir(MK-0518) | ≥97% | 518048-05-0 | 5mg,10mg,50mg,1g |
抑制新型冠狀病毒(2019-nCoV)的2’-O-核糖 甲基轉移酶的DTI預測結果
項目號 | 中文名稱 | 規格 | CAS | 包裝 |
---|---|---|---|---|
E135556 | Efavirenz 依法韋侖 |
≥98%(HPLC) | 154598-52-4 | 10mg,50mg,250mg,1g,5g |
A125825 | Atazanavir 阿扎那韋 |
- | 198904-31-3 | 10mg,50mg,250mg,5g |
參考文獻
Predicting commercially available antiviral drugs that may act on the novel coronavirus (2019-nCoV), Wuhan, China through a drug-target interaction deep learning model.